GLPG2534_product_DataBase

Bioactivity	GLPG2534 is an orally active and selective IRAK4 inhibitor, with IC50 values of 6.4 nM and 3.5 nM for human and mouse IRAK4. GLPG2534 can be used for the research of inflammatory skin diseases[1].
Invitro	GLPG2534 抑制 IL-1β 驱动的 IL-6 释放，IC50 为 55 nM[1]。GLPG2534 抑制 TNF-α 驱动的 IL-6 释放，IC50 为 6.6 μM[1]。GLPG2534 (0.1-10 μM，16 小时) 抑制鞭毛蛋白刺激的角质形成细胞中 S100A7、DEFB4A、CXCL8、TNF 的表达[1]。
In Vivo	GLPG2534 (0.3-10 mg/kg，口服) 抑制小鼠血液中 CL097 驱动的 TNF-α 释放[1]。GLPG2534 (10 和 30 mg/kg，口服，每天两次) 减轻银屑病样小鼠模型中的炎症[1]。GLPG2534 (3-30 mg/kg，p.o.，b.i.d. 5 天) 减轻小鼠 IL-33 和 MC903 诱导的 AD 样皮肤炎症的发展[1]。 Animal Model:
Name	GLPG2534
CAS	2095615-97-5
Formula	C21H24N6O4
Molar Mass	424.45
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Lavazais S, et al. IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases. Sci Transl Med. 2023 Feb 15;15(683):eabj3289.

PeptideDB